EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sinovac Biotech's enterprise value is $-6,773.0 Mil.
Sinovac Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-800.9 Mil. Therefore, Sinovac Biotech's EV-to-EBITDA for today is 8.46.
The historical rank and industry rank for Sinovac Biotech's EV-to-EBITDA or its related term are showing as below:
SVA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -36.64 Med: 7.52 Max: 67.73
Current: 8.46
During the past 13 years, the highest EV-to-EBITDA of Sinovac Biotech was 67.73. The lowest was -36.64. And the median was 7.52.
SVA's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.005
vs SVA: 8.46
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Sinovac Biotech's stock price is $6.47.
Sinovac Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-3.620. Therefore, Sinovac Biotech's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Sinovac Biotech EV-to-EBITDA Historical Data
The historical data trend for Sinovac Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sinovac Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinovac Biotech EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Sinovac Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sinovac Biotech's EV-to-EBITDA falls into.
Sinovac Biotech EV-to-EBITDA Calculation
Sinovac Biotech's EV-to-EBITDA for today is calculated as:
Sinovac Biotech's current Enterprise Value is $-6,773.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinovac Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-800.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sinovac Biotech's PE Ratio for today is calculated as:
Sinovac Biotech's share price for today is $6.47.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinovac Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-3.620.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Sinovac Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Sinovac Biotech (Sinovac Biotech) Business Description
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SVA has been successfully added to your 